IFITM1 and hepatocellular carcinoma: Moreover, aberrant expressions of IFITM1 detected through cancer array profiling, immunohistochemistry, RT-PCR, immunoblotting, and immunofluorescence analysis were verified in colorectal cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma (HNSCC), gallbladder, and ovarian cancer (6, 8, 23, 44–46).